EWTX vs. SNDX, AMRX, NAMS, GLPG, AMPH, DCPH, AGIO, GPCR, KROS, and RCKT
Should you be buying Edgewise Therapeutics stock or one of its competitors? The main competitors of Edgewise Therapeutics include Syndax Pharmaceuticals (SNDX), Amneal Pharmaceuticals (AMRX), NewAmsterdam Pharma (NAMS), Galapagos (GLPG), Amphastar Pharmaceuticals (AMPH), Deciphera Pharmaceuticals (DCPH), Agios Pharmaceuticals (AGIO), Structure Therapeutics (GPCR), Keros Therapeutics (KROS), and Rocket Pharmaceuticals (RCKT). These companies are all part of the "pharmaceutical preparations" industry.
Syndax Pharmaceuticals (NASDAQ:SNDX) and Edgewise Therapeutics (NASDAQ:EWTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, community ranking, media sentiment, institutional ownership and valuation.
Syndax Pharmaceuticals' return on equity of -32.06% beat Edgewise Therapeutics' return on equity.
Syndax Pharmaceuticals received 347 more outperform votes than Edgewise Therapeutics when rated by MarketBeat users. Likewise, 64.73% of users gave Syndax Pharmaceuticals an outperform vote while only 62.50% of users gave Edgewise Therapeutics an outperform vote.
Edgewise Therapeutics has lower revenue, but higher earnings than Syndax Pharmaceuticals. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Edgewise Therapeutics had 4 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 19 mentions for Edgewise Therapeutics and 15 mentions for Syndax Pharmaceuticals. Edgewise Therapeutics' average media sentiment score of 0.45 beat Syndax Pharmaceuticals' score of 0.16 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.
Syndax Pharmaceuticals has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500.
Syndax Pharmaceuticals presently has a consensus price target of $34.42, suggesting a potential upside of 58.75%. Edgewise Therapeutics has a consensus price target of $31.20, suggesting a potential upside of 66.13%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Edgewise Therapeutics is more favorable than Syndax Pharmaceuticals.
Summary
Syndax Pharmaceuticals and Edgewise Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get Edgewise Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Edgewise Therapeutics Competitors List
Related Companies and Tools
